China Biologic Products: MSCI ESG Rating Elevated to AA, with R&D Expenses in the Past Three Years Surpassing 13 Billion Yuan

Question AI · What are the key drivers behind the rapid rise in ESG ratings for China Biopharmaceuticals?

On March 23, China Biopharmaceuticals announced that the internationally authoritative index provider MSCI (Morgan Stanley Capital International) released its latest ESG (Environmental, Social, and Governance) ratings. With outstanding practices in ESG, China Biopharmaceuticals achieved a leap from A to AA rating within two years.

China Biopharmaceuticals was listed on the Hong Kong Stock Exchange in 2020. Since 2017, it has voluntarily disclosed ESG reports for ten consecutive years, demonstrating the company’s commitment to long-term sustainable development. In 2021, China Biopharmaceuticals formulated a “Three-Year ESG Development Plan,” establishing a scientific planning system that promotes the integration of long-term and short-term strategies and the coordination of comprehensive and specialized plans. By 2024, the company completed its “First ESG Three-Year Plan,” and in 2025, it entered the full implementation stage of the “Second ESG Three-Year Plan,” aiming to be a pioneer in the Chinese pharmaceutical industry by launching multiple innovative initiatives and setting a benchmark for sustainable development in China’s pharmaceutical sector.

In the field of environmental sustainability, China Biopharmaceuticals actively responds to the national “30·60” dual carbon goals. It was the first in the Chinese pharmaceutical industry to release a carbon neutrality target plan, with several major pollutant emission intensities decreasing by more than 10% annually for five consecutive years. In March 2026, the “14th Five-Year Plan” proposed comprehensive control of total carbon emissions and emission intensity. In 2025, China Biopharmaceuticals achieved a synchronized reduction in both total carbon emissions and intensity for the first time, contributing to China’s carbon peak goals. Currently, three of its member companies have been awarded the national “Green Factory” title, and its green and sustainable practices have received widespread recognition.

Over the past three years, China Biopharmaceuticals has invested over 13 billion RMB in R&D, with annual growth rates exceeding 15%. It has also established extensive collaborations with more than 30 biotech, biopharma, and multinational companies through “bringing in” and “going global” strategies, actively contributing Chinese strength to global health initiatives. At the beginning of 2026, China Biopharmaceuticals partnered with Sanofi on the licensing of the rare disease drug Rova-T, breaking the perception that niche markets rarely produce blockbuster products. Over the past three years, its key products have served more than 160 million patients, with 13 rare disease drugs in clinical or higher stages.

Additionally, China Biopharmaceuticals places great importance on talent development, systematically implementing “Employee Care Programs (EAP)” and specialized training initiatives to promote mutual growth of the company and its employees. While continuously enhancing its sustainable development capabilities, it actively participates in charitable and public welfare activities. In November 2025, following a sudden fire in Dapu, Hong Kong, the company promptly donated 10 million RMB in cash and medicines to support disaster relief and transitional living for affected families. Focusing on disaster relief, rural revitalization, and accessible healthcare, it has donated over 150 million RMB in the past three years, demonstrating its commitment to social responsibility.

(China Biopharmaceuticals Announcement)